Sales & Marketing How data is critical to commercialising drugs for rare disea... Orphan drugs are designed to treat rare diseases, but “rare” is a relative term.
R&D Pharma gets ruthless as job losses mount across industry The industry is showing its teeth, as companies have started slashing positions.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
